Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019GBI Research - October 18, 2013 - 123 Pages - SKU: XGBR5137391 |
Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019
Summary
GBI Research has released its latest report for the pharmaceuticals industry, “Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 ... read the full abstract
Summary
GBI Research has released its latest report for the pharmaceuticals industry, “Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 ... read the full abstract
More Drug Discovery reports by GBI Research
Fungal Foot Infections Drug Development Pipeline Review, 2018 by GBI Research
Fungal Foot Infections Drug Development Pipeline Review, 2018SummaryOnychomycosis and athlete’s foot are non-life threatening fungal infections that most commonly affect the toenails and the feet ...
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 by GBI Research
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018SummaryBoth NASH and NAFLD occur largely as a result of prolonged ...
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs by GBI Research
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster ...
Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market by GBI Research
See all reports like this >>Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the MarketSummaryUveitis refers to inflammation ...
Since 1998, MarketResearch.com has provided companies with the business intelligence and research they need to make informed decisions.
We provide information on products, trends, regions, demographics, industries and companies from our collection of over 700 research publishers and 400,000 research reports.
About Us
We provide information on products, trends, regions, demographics, industries and companies from our collection of over 700 research publishers and 400,000 research reports.
About Us
